|
ColoVantage™
Colorectal Cancer is the fourth most common cancer in the United States: however, it is the second leading cause of cancer related deaths. The high number of deaths is likely due to the following facts:
- The 5-year survival rate dramatically drops from about 90% for patients diagnosed with early stage disease to 70% and 12% for those diagnosed with regional and distant stage disease respectively.
- Only about 40% of patients are diagnosed at an early stage
- Only about half of adults age 50 and over have been screened
Current screening methods are either moderately invasive or require collection of a stool sample. Special patient preparation steps are often involved. These, among other things, may be barriers to screening.
ColoVantage™ represents an important medical advancement in that it is a plasma-based test (blood test) that requires no patient preparation. It detects circulating methylated DNA from the SEPT9 gene, which is involved in cytokinesis and cell cycle control. A case-control study performed at Quest Diagnostics showed that the ColoVantage™ test is 70% sensitive for CRC detection at a specificity of 89%! ColoVantage™ has successfully detected cancer at all stages; however, the number of patients at each stage of cancer was too small to derive stage-specific sensitivity data. A similar test demonstrated a sensitivity of 67% and a specificity of 88% in a prospective study of almost 8000 people.
The test is recommended for screen-eligible patients who have previously avoided established colorectal cancer screening methods such as colonoscopy, fecal occult blood tests, and fecal immunochemical tests (FITS). A person whose ColoVantage™ test result is positive may be at increased risk for colorectal cancer and further evaluation should be considered. ColoVantage™ is not a replacement test for a colonoscopy.
ORDER YOUR ColoVantage™ by call 1-800-541-8110. One of our representatives will be happy to guide you through the simple steps.
Order yours today!
TEST PREP: NONE
COST: CALL FOR PRICING
|
